P-103

Posaconazole solution

2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

• Formule empirique (notation de Hill): C₃₇H₄₂F₂N₈O₄
• Numéro CAS: 171228-49-2
• Poids moléculaire : 700.78
• Numéro CE : 200-659-6
• Numéro MDL: MFCD00941162
• Code UNSPSC : 41116107
• Nomenclature NACRES : NA.24

Propriétés

• Qualité: certified reference material
• Forme: liquid
• Caractéristiques: (Snap-N-Spike^®)
• Conditionnement: ampule of 1 mL
• Fabricant/nom de marque: Cerilliant^®
• Concentration: 2.0 mg/mL in methanol
• Technique(s): gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• Application(s): clinical testing
• Format: single component solution
• Température de stockage: room temp
• InChI: 1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
• Clé InChI: RAGOYPUPXAKGKH-XAKZXMRKSA-N

Description

Description générale

A certified Snap-N-Spike^® Solution suitable as starting material for calibrators, controls, or linearity standards in posaconazol therapeutic drug monitoring or clinical and diagnostic testing applications in patient blood, serum, or plasma samples by LC-MS/MS or HPLC. Sold under trade names Noxafil^® and Posanol, posaconazole is a triazole antifungal drug prescribed for treatment of invasive fungal infections in severely immunocompromised patients.

Application

• Pharmacokinetic modeling in pediatric patients: Posaconazole intravenous solution and oral powder suspension formulations are studied for their pharmacokinetics in pediatric patients with neutropenia, highlighting the solution′s role in optimizing dosing regimens (Winchell et al., 2024).


• Enhanced solubility and bioavailability: Posaconazole antifungal solution is utilized in the development of amorphous solid dispersions with poly(vinylpyridine-co-vinylpyridine N-oxide) excipients, which mediate rapid dissolution and sustained supersaturation, improving its therapeutic efficacy (Liu et al., 2024).


• Nanoformulation for oral delivery: A posaconazole-loaded phospholipid-based nanoformulation developed through design of experiments, machine learning, and TOPSIS optimizes oral delivery, enhancing the antifungal′s absorption and therapeutic profile (Bayat et al., 2024).


• Cost-utility analysis in fungal prophylaxis: Research on posaconazole solution′s cost-effectiveness in preventing invasive fungal infections among leukemia patients undergoing chemotherapy underscores its potential economic benefits in healthcare settings (Pungprasert et al., 2024).


• Cerebrospinal fluid concentrations: Studies assessing the concentrations of posaconazole in cerebrospinal fluid of pediatric leukemia patients validate the solution′s penetration and potential effectiveness in treating central nervous system infections (Körholz et al., 2024).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Noxafil is a registered trademark of MSD

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Pictogrammes: GHS02,GHS06,GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H225,H301 + H311 + H331,H370
• Conseils de prudence: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• Classification des risques: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Organes cibles: Eyes,Central nervous system
• Code de la classe de stockage: 3 - Flammable liquids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): 49.5 °F
• Point d'éclair (°C): 9.7 °C